{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=100",
    "query": {
      "condition": "Multi Center",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 6602,
    "total_pages": 661,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T00:10:50.040Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00776009",
      "title": "Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 165,
      "start_date": "2008-10",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00776009"
    },
    {
      "nct_id": "NCT00615199",
      "title": "A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2008-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615199"
    },
    {
      "nct_id": "NCT00388999",
      "title": "Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enzon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2006-09",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388999"
    },
    {
      "nct_id": "NCT00108849",
      "title": "Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause",
        "Postmenopausal Vaginal Atrophy"
      ],
      "interventions": [
        {
          "name": "estradiol, 10 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 309,
      "start_date": "2005-03",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108849"
    },
    {
      "nct_id": "NCT02900248",
      "title": "CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms",
        "Lung Neoplasms",
        "Colon Neoplasms",
        "Breast Neoplasms",
        "Pancreatic Neoplasms",
        "Prostate Neoplasms",
        "Kidney Neoplasms",
        "Liver Neoplasms",
        "Rectal Neoplasms",
        "Hematologic Neoplasms",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes",
        "Ovarian Neoplasms",
        "Bladder Neoplasms",
        "Testicular Neoplasms",
        "Endometrial Neoplasms",
        "Brain Neoplasms",
        "Biliary Tract Neoplasms",
        "Head and Neck Neoplasms",
        "Uterine Cervical Neoplasms",
        "Skin Neoplasms",
        "Melanoma",
        "Gastric Neoplasms",
        "Anal Neoplasms",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Provider determined",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CureOne",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-10-02",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 1,
      "location_summary": "Idaho Falls, Idaho",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900248"
    },
    {
      "nct_id": "NCT02653443",
      "title": "A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous apheresis Conventional untreated Platelet Components",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cerus Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-12",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2018-01-26",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 2,
      "location_summary": "Lebanon, New Hampshire • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653443"
    },
    {
      "nct_id": "NCT06655207",
      "title": "Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post Partum Haemorrhage",
        "Maternal Care Patterns",
        "High Risk Pregnancy"
      ],
      "interventions": [
        {
          "name": "Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Baymatob Operations Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2025-08-06",
      "completion_date": "2026-07-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06655207"
    },
    {
      "nct_id": "NCT06410300",
      "title": "Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Curative Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Immunotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Bo Lu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2024-04-19",
      "completion_date": "2030-04-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 3,
      "location_summary": "Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06410300"
    },
    {
      "nct_id": "NCT00337207",
      "title": "Bevacizumab in Treating Patients With Recurrent or Progressive Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2006-03",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00337207"
    },
    {
      "nct_id": "NCT05199584",
      "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors With PTCH1 Loss-of-function Mutations"
      ],
      "interventions": [
        {
          "name": "ENV-101 (taladegib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Biomedicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-05-24",
      "completion_date": "2024-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-11T00:10:50.040Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199584"
    }
  ]
}